Assessment of the relationship between fragmented QRS and cardiac iron overload in patients with beta-thalassemia major

Nermin Bayar, Erdal Kurtoğlu*, Şakir Arslan, Zehra Erkal, Serkan Çay¹, Göksel Çağrıç, Burak Deveci*, Selçuk Küçükseymen

Clinics of Cardiology and *Hematology, Antalya Education and Research Hospital; Antalya-Turkey
¹Clinic of Cardiology, Türkiye Yüksek İhtisas Education and Research Hospital; Ankara-Turkey

ABSTRACT

Objective: Beta-thalassemia major (TM) is a genetic hemoglobin disorder causing chronic hemolytic anemia. Since cardiac insufficiency and arrhythmias are the primary causes of mortality in such patients, monitoring of cardiac iron load is important in management of the disorder. The purpose of this study was to investigate the importance of fragmented QRS (fQRS) and its relation to the cardiac T2* value for the evaluation of cardiac iron load in TM patients.

Methods: This retrospective study included 103 TM patients. The patients’ T2* values, measured by cardiac MRI and 12-lead surface ECGs, were interpreted. The cardiac T2* values under 20 were considered as cardiac iron overload. The relationship between the cardiac T2* value and fQRS in ECG was investigated.

Results: The median age of the patients was 22.6±6.6 years. All patients were on regular blood transfusions and iron chelators. The patients had no risk factors for coronary artery disease. In 50 (48%) patients fQRS was detected, and in 37 (74%) of these the T2* values were low. 86% of patients with cardiac involvement (37) had fQRS, but 22% of patients with non-involvement (13) had fQRS (p<0.001).

Conclusion: Since cardiac involvement is the primary cause of mortality in TM patients, the early diagnosis of cardiac dysfunction is of vital importance. The search for fQRS in the ECGs of these patients, particularly when cardiac T2* values cannot be determined and followed, is a non-expensive and easy-to-attain method for therapy management. (Anatolian J Cardiol 2015; 15: 132-6)

Key words: beta-thalassemia major, electrocardiography, fragmented QRS, cardiac MR imaging, T2* value

Introduction

Beta-thalassemia major (TM), is a frequently encountered monogenic disorder that decreases the synthesis of globin, a protein component of hemoglobin. TM patients require repeated blood transfusions because of deep anemia due to ineffective erythropoiesis (1). Peripheral hemolysis, the increased intestinal absorption of iron, ineffective erythropoiesis, and, most importantly, repeated blood transfusions cause an overload of iron in the body (2). Iron accumulation starts in the reticuloendothelial system (RES). The iron saturation of RES is followed by iron accumulation in other organs, namely, endocrine glands, liver and myocardium. In TM patients, myocardium is not the first site of iron accumulation, but it is the organ where the most serious complications occur (3, 4).

In TM patients cardiac insufficiency and arrhythmias, due to cardiac iron overload, are the major causes of mortality (5). Thus, cardiac MRI and regular measurements of the T2* value are recommended for evaluating cardiac iron load (6). However, since MRI is expensive and not easily attained for early diagnosis of cardiac dysfunction, more practical methods have been sought.

In recent studies, the presence of fQRS at the surface ECG has shown to be related with conditions leading to myocardial activation nonhomogeneous (7). Cardiac iron overload and fibrosis in patients with TM, may result in a non-homogeneous activation. This study was planned to investigate the relationship between fragmented QRS (fQRS), observed in non-homogeneous cardiac activations like scar formation and fibrosis, and cardiac iron overload and so to cardiac T2* value in patients with TM.

Methods

This retrospective study included 103 TM patients between 15 and 40 years of age who were followed at our Center for
Thalassemia. Patients with diabetes mellitus, hypertension, ischemic heart disease and smokers were excluded, beside individuals were excluded from the study, if they had a history of coronary artery disease or regional wall motion abnormalities under resting transthorasic echocardiography examination. Patients were divided into four different treatment groups of deferiprone, deferoxamine, deferiprone-deferoxamine combination, deferasirox and were receiving the same treatment regimen for at least two years. The annual cardiac MR T2* values and annual ECGs of the patients were evaluated. The patients' 12-lead surface ECGs were analyzed for the presence of fQRS (Nihon Kohden-Cardiofax S ECG-1250K, filter range 0.5Hz to 150Hz, AC filter 60Hz, 25 mm/s,10 mm/mV). The fQRS pattern was identified by the presence of different RSR' patterns in the presence or absence of the Q wave in two adjacent derivations (QRS duration, <120 ms); additional R wave (R' wave) or notching in the nadir of the R or S wave or by the presence of more than one R wave in the absence of typical bundle branch block (7). The measurement of cardiac MR T2* was evaluated according to the description by Westwood et al. (8). The cardiac T2* value <20 ms was accepted as cardiac iron overload. The relationship between the cardiac T2* value and fQRS in ECG was investigated.

Statistical analysis

Data were analyzed with the SPSS software version 15.0 for Windows. Categorical variables were presented as frequency and percentage. The χ² test and Fisher's exact test were used to compare categorical variables. The Kolmogorov-Smirnov test was used to assess the distribution of continuous variables. Student’s t-test was used for variables with normal distribution and the values were presented as mean±SD. Continuous variables without normal distribution were analyzed using Mann-Whitney U test and obtained values were presented as median (50th) values and interquantile ranges (25th and 75th). Multivariate logistic regression analysis was used to evaluate the independent associates of the risk of cardiac involvement. Parameters with a p value of less than 0.1 in univariate analysis were included in the model. The odds ratios (OR) and 95% confidence intervals (CI) were calculated. A two-tailed p value of <0.05 was considered statistically significant.

Results

The study included 103 patients with TM of whom 46 were males. The median age of the patients was 22.6±6.6 years. All patients were on regular blood transfusions and iron chelators. Patients had no risk factor other than smoking for coronary artery disease. Between the groups with and without cardiac involvement, there was no difference in left ventricular ejection fraction, age, gender (Table 1). The study showed the presence of a significant relationship between cardiac T2* value and fQRS in ECG. In 50 (48%) patients fQRS was detected and in 37 (74%) of these the T2* value was found low. 86% of patients with cardiac involvement (37) had fQRS, but 22% of patients with non-involvement (13) had fQRS (p<0.001) (Fig. 1). Mean age of patients with fQRS was 24.4±7.7 years, while those without fQRS was 21.4±6.6 years (p=0.01). Between the groups with and without fQRS, there was no difference in left ventricular ejection fraction and sex.

In logistic regression analysis for cardiac iron overload, significant correlation was found in univariate analysis (OR, 22.3; 95% CI, 7.7-64.3; p<0.001) and multivariate analysis (OR, 19.0; 95% CI, 5.2-69.7; p<0.001) between the presence of cardiac iron overload and the presence of fQRS. Univariate analysis are used according to types of iron chelates, deferoxamine or deferasirox users compared with non-users have a low incidence of cardiac involvement.

Bayar et al.  
Fragmented QRS and thalassemia 
Anatolian J Cardiol 2015; 15: 132-6 

Figure 1. Patients with cardiac involvement, have been seen more frequently in the presence of fQRS

Table 1. Demographic characteristics with and without cardiac involvement

| Variables | Cardiac involvement (+) (n=43) | Cardiac involvement (-) (n=60) | P  |
|-----------|-------------------------------|-------------------------------|----|
| Age, years | 22 (20-27) | 21 (18-25) | 0.299 |
| Male gender, n (%) | 19 (44%) | 27 (45%) | 0.935 |
| Triglyceride, mg/dL | 165±93 | 122±46 | 0.003 |
| LDL, mg/dL | 68±37 | 54±24 | 0.029 |
| HDL, mg/dL | 28±11 | 30±10 | 0.384 |
| Total cholesterol, mg/dL | 128±47 | 110±29 | 0.019 |
| Hemoglobin, g/dL | 8 (8-9) | 8 (8-9) | 0.634 |
| WBC, 10³/mm³ | 10 (6-25) | 8 (6-17) | 0.278 |
| PLT, 10³/mm³ | 418±218 | 405±224 | 0.775 |
| EDD, mm | 45±4 | 47±4 | 0.020 |
| ESD, mm | 28±4 | 30±4 | 0.050 |
| LVEF, % | 60 (58-65) | 60 (60-65) | 0.214 |
| fQRS present | 37 (86%) | 13 (22%) | <0.001 |
| T2* value | 13±3 | 33±10 | <0.001 |

Which show a normal distribution mean±SD, not show a normal distribution median and 75. percentile EDD - left ventricular end-diastolic diameter; ESD - left ventricular end-systolic diameter; LVEF - left ventricular ejection fraction; WBC - white blood cell
were evaluated in association with cardiac involvement.

Table 3. Iron chelates used in association with cardiac involvement were evaluated

| Variables              | Cardiac involvement (+) | Cardiac involvement (-) | \( P \) |
|------------------------|-------------------------|-------------------------|--------|
| Deferiprone            | 19 (44%)                | 18 (30%)                | 0.139  |
| Deferoxamine           | 24 (56%)                | 19 (32%)                | 0.012  |
| Deferiprone+Deferoxamine| 13 (30%)               | 9 (15%)                 | 0.054  |
| Deferasirox            | 13 (30%)                | 32 (53%)                | 0.016  |

Table 4. Iron chelates used in association with the presence of fQRS, were evaluated

| Variables              | fQRS (+) \( n=50 \) | fQRS (-) \( n=53 \) | \( P \) |
|------------------------|---------------------|---------------------|--------|
| Deferiprone            | 22 (44%)            | 15 (28%)            | 0.097  |
| Deferoxamine           | 30 (60%)            | 13 (25%)            | <0.001 |
| Deferiprone+Deferoxamine| 14 (28%)           | 8 (15%)             | 0.110  |
| Deferasirox            | 12 (24%)            | 33 (62%)            | <0.001 |

Table 5. In multivariate regression analysis for fQRS, cardiac iron overload was significantly correlated with the presence fQRS

| Variables              | OR       | 95% CI    | \( P \) |
|------------------------|----------|-----------|--------|
| Age (For every 1 year) | 1.064    | 0.993-1.141| 0.079  |
| Deferiprone            | 0.320    | 0.059-1.750| 0.189  |
| Deferoxamine           | 0.903    | 0.157-5.190| 0.909  |
| Deferasirox            | 0.087    | 0.008-0.941| 0.044  |
| Cardiac involvement    | 27.488   | 8.170-92.481| <0.001 |

involvement was seen more (Table 2). In deferoxamine or deferasirox users, cardiac iron overload is less than non-users, fQRS presence of these patients also have been seen less (Table 3, 4).

Multivariate logistic regression analysis was used for the presence of fQRS and cardiac iron overload was significantly correlated with the presence fQRS (OR, 27.4; 95% CI, 8.170-92.481; \( p < 0.001 \)). The relationship was detected at the border for used iron chelator deferasirox, there was no difference for the other medications (Table 5).

### Discussion

This study has shown that in patients with TM the presence of fQRS in surface ECG is associated with a decrease in cardiac T2* and thus with cardiac iron overload. The quantity of iron overload varies greatly, but is highest in the subepicardium followed by subendocardium, frequently yielding a patch-like image (9, 10). The accumulation occurs mainly in the myocardium (particularly in the interventricular septum and ventricular free wall) rather than in the atrioventricular conduction system (11).

Studies with tissue Doppler imaging (TDI) or radionuclide angiography have shown regional non-uniformity of left ventricular wall movement even in the early stage of iron accumulation, a finding which indicates that in the myocardium, iron is deposited non-homogenously and in a patch-like pattern. However, TDI and radionuclide angiography cannot assess the cardiac iron content (12, 13). For the evaluation of cardiac iron overload, cardiac MR and measurement of T2* value are recommended. Studies have shown that cardiac T2* is highly predictive over 1 year for the development of heart failure and arrhythmia. Low T2* values are associated with the occurrence of myocardial dysfunction. A study involving 652 patients with TM has reported that cardiac T2* values of <20 ms are significantly associated with the risk of arrhythmia and for patients with T2* values of <10 ms with risk of cardiac insufficiency (14).

Cardiac iron overload first leads to delay or blockage in myocardial electrical conduction and later to disorders in myocardial contraction. In the early stage of the disorder, as criteria, bradycardia, changes in ST-T, seldom atrial and ventricular premature systoles, first-degree atroventricular block, and left ventricular hypertrophy are observed (15, 16). In the late stage of the disorder, frequent atrial and ventricular premature systoles, supraventricular tachycardia, second-degree or complete cardiac block can occur (5, 16). Additionally, prolongation of QT and PR intervals subsequent to slowing of conduction in cardiac muscle has been reported (17). Kurysh et al. (18) reported the presence of increased QT dispersion in 14 of 24 TM patients. Another study (19) has shown that ventricular late potentials (VLP) are more frequent in TM patients and that ventricular premature systoles and transient ventricular tachycardia occur more often in those with VLP. A recent study (20) has reported that the P wave dispersion, the free predictor of atrial fibrillation, is prolonged and associated with cardiac T2* value in such patients.

Among TM patients, cardiac insufficiency usually develops in those receiving inadequate chelation therapy. Excess free iron that cannot be further deposited in the lysosomes of myocytes exerts a toxic effect on the cell; it impairs the redox reactions and gene modulations, directly interacts with ion channels, stimulates the production of free radicals, and leads to oxidative membrane impairment. As a result of the impairment of energy production within mitochondria, cardiac dysfunction occurs (21, 22). Under normal conditions myocytes tonically suppress fibroblast proliferation, but this paracrine effect is reduced by myocyte iron loading. This observation explains the mechanism for iron-induced cardiac fibrosis in TM patients (23).

In a study on the evaluation of myocardial scar in 115 TM patients by delayed enhancement (DE) cardiac MRI (24), DE
areas were detected in 28 patients (24%) and in 26 of these patch-like fibrosis was observed. The study further reported that since the patients with scar formation were older than the others, myocardial fibrosis/necrosis was more frequent in TM patients than in normal individuals and that this situation is a time-dependent process and associated with KV risk factors (24). In our study, we also found that the incidence of fQRS increased with age, supporting time-dependent fibrosis. Another investigation by Kirk et al. (25) reported that in TM patients, macroscopic myocardial fibrosis was seldom observed and that fibrosis could be microscopic and reversible in such cases. Another study (26) reported that the characteristic histopathological finding in iron overloaded organs was iron deposit and/or interstitial fibrosis.

Since the main cause of mortality in TM patients is cardiac insufficiency, the early diagnosis of cardiac dysfunction and the modification of therapy accordingly are of utmost importance. Such patients can have regional non-uniformity of left ventricular wall movement as an early sign of cardiac involvement in spite of intact global ventricular function. A study on the early diagnosis of cardiac dysfunction by TDI in asymptomatic TM patients (27) showed regional systolic dysfunction of the lateral free wall and regional diastolic dysfunction in the septal and right ventricular wall. Another investigation with TDI (28) reported a significant relationship between the presence of fQRS and impairment of TDI parameters in TM patients.

The mechanisms for the development of fQRS have not been fully clarified. However, fQRS has been shown to be related to conditions of non-homogeneous depolarization, namely, myocardial scar, fibrosis or ischemia (29-33). In research, the presence of fQRS has been reported to be helpful in the evaluation of arrhythmic events and cardiac risk in different patient groups. The study which includes patients presenting with ST-segment elevation myocardial infarction, the presence of fQRS in application of ECG, may help to identify high-risk cardiac patients have been reported (34). In another study which includes patients with coronary artery disease, the presence of fQRS on ECG in patients with prior CABG, has been shown to have a higher risk of developing AF in the postoperative period (35). Also in researches in patients with arrhythmogenic right ventricular dysplasia (ARVD) and hypertrophic cardiomyopathy, presence of fQRS on the surface ECG, is reported to be a predictor for arrhythmic events (36, 37).

Iron overload and fibrosis in TM patients can cause non-homogeneous activation. In our study, the presence of fQRS on surface ECG, have been associated with cardiac iron overload. In view of this finding, during patient follow-up the emergence of fQRS in surface ECG is critical and would require the revision of treatment regimens. Also the presence of a significant relationship between age and the presence of fQRS and low T2* values upholds the theory that cardiac iron load increases parallel to age. An annual cardiac MRI is advised for MR patients under follow-up care. Additionally, a surface ECG to seek fQRS made at the time of visit for blood transfusion would contribute highly to the early diagnosis of cardiac dysfunction and evaluation of the outcome of treatment.

Study limitations

Since the study did not include the follow-up of the cases, the effect of fQRS on the prognosis could not be evaluated.

Conclusion

In TM patients the presence of fQRS in surface ECG has a high predictive value for cardiac iron overload. The detection of fQRS could be indicative of the need for closer monitoring and aggressive chelation therapy.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept - N.B., E.K.; Design - N.B., S.K.; Supervision - Ş.A.; Materials - B.D., S.K.; Data collection &/or processing - E.K., Z.E., S.Ç., G.Ç.; Analysis &/or interpretation - E.K., S.Ç., G.Ç.; Literature search - B.D., Z.E.; Writing - N.B.; Critical review - E.K., Ş.A.

References

1. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in beta-thalassemia intermedia. Lancet 1979; 2: 819-21. [CrossRef]
2. Herschko C, Link G, Cabanchik I. Pathophysiology of iron overload. Ann NY Acad Sci 1998; 850: 191-201. [CrossRef]
3. Zurlo MG, De Stefano P, Borgha-Pignatti C, Di Palm A, Piga A, Meleveni C, et al. Survival and causes of death in thalassemia major. Lancet 1989; 2: 27-30. [CrossRef]
4. Borgha-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227-31. [CrossRef]
5. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamos CA. Heart failure in beta thalassemia: A 5-year follow-up study. Am J Med 2001; 111: 349-54. [CrossRef]
6. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star(T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-9. [CrossRef]
7. Das MK, Khan B, Jacob S, Kumar A, Mahenthiran J. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 2006; 113: 2495-501. [CrossRef]
8. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, et al. A single breath-hold multi-echo T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18: 33-9. [CrossRef]
9. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971; 51: 209-21. [CrossRef]
10. Bartfay WJ, Butany J, Lehotay DC, Sole MJ, Hou D, Bartfay E, et al. A biochemical,histochemical, and electron microscopic study on
the effects of iron-loading on the hearts of mice. Cardiovasc Pathol 1999; 8: 305-14. [CrossRef]
11. Schellhammer PF, Engle MA, Hagstrom JW. Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation 1967; 35: 631-7. [CrossRef]
12. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue Doppler echocardiography in patient with thalassemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 2003; 24: 113-9. [CrossRef]
13. De Chiara B, Crivellaro W, Sara R, Ruffini L, Parolini M, Fesslovà V, et al. Early detection of cardiac dysfunction in thalassemic patients by radionuclide angiography and heart rate variability analysis. Eur J Haematol 2005; 74: 517-22. [CrossRef]
14. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8. [CrossRef]
15. Veglio F, Melchio R, Rabbia F, Molino P, Genova GC, Martini G, et al. Blood pressure and heart rate in young thalassemia major patients. Am J Hypertens 1998; 11: 539-47. [CrossRef]
16. Kaye SB, Owen M. Cardiac arrhythmias in thalassemia major: Evaluation of chelation treatment using ambulatory monitoring. B Med J 1978; 1: 342. [CrossRef]
17. Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, et al. Molecular mechanisms of angiotensin II in modulating cardiac function: Intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 1997; 29: 2893-902. [CrossRef]
18. Kuryshchev YA, Brittenham GM, Fujioka H, Kann P, Shieh CC, Cohen SA, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation 1999; 100: 675-83. [CrossRef]
19. Franzoni F, Galetta F, Di Muro C, Buti G, Pentimone F, Di Muro A, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Circulation 1999; 100: 675-83. [CrossRef]
20. Russo V, Rago A, Pannone B, Di Meo F, Papa AA, Mayer MC, et al. Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients. Int J Hematol 2011; 93: 446-51. [CrossRef]
21. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev 2008; 22: 14-21. [CrossRef]
22. Aessopos A, Farmakis D, Andreopoulos A, Tsironi M. Assessment and treatment of cardiac iron overload in thalassemia. Hemoglobin 2009; 33: 87-92. [CrossRef]
23. Liu Y, Templeton DM. The effects of cardiac myocytes on interstitial fibroblasts in toxic iron overload. Cardiovasc Toxicol 2001; 1: 299-308. [CrossRef]
24. Pepe A, Positano V, Capra M, Maggio A, Pinto CL, Spasiano A, et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassemia major. Heart 2009; 95: 1688-93. [CrossRef]
25. Kirk P, Carpenter JP, Tanner MA, Pennell DJ. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011; 13: 8. [CrossRef]
26. Stayanova E, Cloutier G, Felfty H, Lemsaddek W, Ah-Son N, Trudel M. Evidence for a novel mechanism independent of myocardial iron in beta-thalassemia cardiac pathogenesis. PLoS ONE 2012; 7: 52128. [CrossRef]
27. Hamdy AM. Use of strain and tissue velocity imaging for early detection of regional myocardial dysfunction in patients with beta thalassemia. Eur J Echocardiography 2007; 8: 102-9. [CrossRef]
28. Büyükkaya E, Karakaş MF, Kurt M, Bilen P, Yalçın Ş, Çelik M, et al. The relation of fragmented QRS with tissue Doppler derived parameters in patient with b-thalassemia major. Clin Invest Med 2012; 35: 334.
29. Flowers NC, Horan LG, Thomas JR, Tolleson WJ. The anatomic basis for high, frequency components in the electrocardiogram. Circulation 1969; 39: 531-9. [CrossRef]
30. Lesh MD, Spear JF, Simson MB. A computer model of the electrocardiogram: what causes fractionation? J Electrocardiol 1988; 21: 69-73. [CrossRef]
31. Friedman PL, Fenoglio JJ, Wit AL. Time course for reversal of electrophysiological and ultrastructural abnormalities in subendocardial Purkinje fibers surviving extensive myocardial infarction in dogs. Circ Res 1975; 36: 127-44. [CrossRef]
32. Wiener I, Mindich B, Pitchon R. Fragmented endocardial electrical activity in patients with ventricular tachycardia: a new guide to surgical therapy. Am Heart J 1984; 107: 86-90. [CrossRef]
33. Başaran Y, Tigen K, Karaahmet T, Bilen P, Yalçın Ş, Çelik M, et al. Fragmented QRS complexes are associated with cardiac fibrosis and significant intraventricular systolic dyssynchrony in nonischemic dilated cardiomyopathy patients with a narrow QRS interval. Echocardiography 2011; 28: 62-8. [CrossRef]
34. Kocaman SA, Çetin M, Karaş T, Erdoğan T, Çanga A, Durakoğlugil E, et al. The importance of fragmented QRS complexes in prediction of myocardial infarction and reperfusion parameters in patients undergoing primary percutaneous coronary intervention. Arch Turk Soc Cardiol 2012; 40: 213-22. [CrossRef]
35. Çetin M, Kocaman SA, Erdoğan T, Durakoğlugil ME, Çiçek Y, Bozköy, Ş, et al. Fragmented QRS complexes are associated with cardiac fibrosis and significant intraventricular systolic dyssynchrony in nonischemic dilated cardiomyopathy patients with a narrow QRS interval. Echocardiography 2011; 28: 62-8. [CrossRef]
36. Femenia F, Arce M, Van Griek J, Trucco M, Martínez de la, et al. Fragmented QRS complex predicts the arrhythmic events in patients with hypotrophic obstructive cardiomyopathy. J Interv Card Electrophysiol 2013; 38: 159-65. [CrossRef]
37. Canpolat U, Kabakçı G, Aytemir K, Dural M, Şahiner L, Yorgun H, et al. Fragmented QRS complex predicts the arrhythmic events in patients with Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Cardiovasc Electrophysiol 2013; 24: 1260-6. [CrossRef]